Anna-Carson R. Uhelski , Margaret Wheless , Elizabeth J. Davis , Rajiv Agarwal
{"title":"I期癌症临床试验患者姑息治疗整合","authors":"Anna-Carson R. Uhelski , Margaret Wheless , Elizabeth J. Davis , Rajiv Agarwal","doi":"10.1016/j.currproblcancer.2023.101022","DOIUrl":null,"url":null,"abstract":"<div><p><span><span>Early integration of palliative care (PC) is recommended as standard of care for patients with advanced cancer. However, challenges remain for both medical oncologists and PC specialists in knowing how to best integrate PC within the dynamic landscape of cancer therapeutics and </span>drug<span> development. Over the last several years in oncology<span>, the success of immunotherapy and molecularly targeted agents has led to a greater demand for novel agents and expansion of objectives of early phase </span></span></span>clinical trials. This has in turn created more nuance when discussing prognosis and supporting patients with advanced disease and their caregivers. This review article presents the current literature to support the integration of PC within investigational oncology, as a mechanism to address the evolving needs of patients and caregivers, during and beyond participation on phase I cancer clinical trials.</p></div>","PeriodicalId":55193,"journal":{"name":"Current Problems in Cancer","volume":"47 5","pages":"Article 101022"},"PeriodicalIF":2.5000,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Palliative care integration for patients on phase I cancer clinical trials\",\"authors\":\"Anna-Carson R. Uhelski , Margaret Wheless , Elizabeth J. Davis , Rajiv Agarwal\",\"doi\":\"10.1016/j.currproblcancer.2023.101022\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p><span><span>Early integration of palliative care (PC) is recommended as standard of care for patients with advanced cancer. However, challenges remain for both medical oncologists and PC specialists in knowing how to best integrate PC within the dynamic landscape of cancer therapeutics and </span>drug<span> development. Over the last several years in oncology<span>, the success of immunotherapy and molecularly targeted agents has led to a greater demand for novel agents and expansion of objectives of early phase </span></span></span>clinical trials. This has in turn created more nuance when discussing prognosis and supporting patients with advanced disease and their caregivers. This review article presents the current literature to support the integration of PC within investigational oncology, as a mechanism to address the evolving needs of patients and caregivers, during and beyond participation on phase I cancer clinical trials.</p></div>\",\"PeriodicalId\":55193,\"journal\":{\"name\":\"Current Problems in Cancer\",\"volume\":\"47 5\",\"pages\":\"Article 101022\"},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2023-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Problems in Cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0147027223000752\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Problems in Cancer","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0147027223000752","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
Palliative care integration for patients on phase I cancer clinical trials
Early integration of palliative care (PC) is recommended as standard of care for patients with advanced cancer. However, challenges remain for both medical oncologists and PC specialists in knowing how to best integrate PC within the dynamic landscape of cancer therapeutics and drug development. Over the last several years in oncology, the success of immunotherapy and molecularly targeted agents has led to a greater demand for novel agents and expansion of objectives of early phase clinical trials. This has in turn created more nuance when discussing prognosis and supporting patients with advanced disease and their caregivers. This review article presents the current literature to support the integration of PC within investigational oncology, as a mechanism to address the evolving needs of patients and caregivers, during and beyond participation on phase I cancer clinical trials.
期刊介绍：
Current Problems in Cancer seeks to promote and disseminate innovative, transformative, and impactful data on patient-oriented cancer research and clinical care. Specifically, the journal''s scope is focused on reporting the results of well-designed cancer studies that influence/alter practice or identify new directions in clinical cancer research. These studies can include novel therapeutic approaches, new strategies for early diagnosis, cancer clinical trials, and supportive care, among others. Papers that focus solely on laboratory-based or basic science research are discouraged. The journal''s format also allows, on occasion, for a multi-faceted overview of a single topic via a curated selection of review articles, while also offering articles that present dynamic material that influences the oncology field.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
